UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the 2022 annual meeting of stockholders of FibroGen, Inc. (“FibroGen” or the “Company”) held on June 16, 2022, the stockholders voted on the three proposals listed below. The proposals are described in detail in the Company’s definitive proxy statement for the 2022 annual meeting of stockholders, filed with the Securities and Exchange Commission on April 29, 2022. The results of the matters voted upon at the meeting were:
(1) |
|
All of the Class II nominees of the board of directors were elected to hold office until the Company’s 2025 annual meeting of stockholders. The nominees were: (i) Suzanne Blaug: 63,460,973 shares of Common Stock voted for, 3,929,703 withheld, and 12,356,413 broker non-votes; (ii) Benjamin F. Cravatt, Ph.D.: 66,689,932 shares of Common Stock voted for, 700,744 withheld, and 12,356,413 broker non-votes; and (iii) Jeffrey L. Edwards: 66,378,082 shares of Common Stock voted for, 1,012,594 withheld, and 12,356,413 broker non-votes. The term of office of Class III directors Enrique Conterno, Aoife Brennan, M.B., B.Ch., and Gerald Lema continues until the Company’s 2023 annual meeting of stockholders. The term of office of Class I directors James A. Schoeneck, Jeffrey W. Henderson, and Maykin Ho., Ph.D., continues until the Company’s 2024 annual meeting of stockholders. |
(2) |
|
The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the 2022 definitive proxy statement: 36,094,036 shares of Common Stock voted for, 31,129,425 against, and 167,215 abstaining. |
(3) |
|
The stockholders ratified the selection of PricewaterhouseCoopers LLP, by the Audit Committee of the FibroGen board of directors, as the independent registered public accounting firm of the Company for the year ending December 31, 2022: 75,170,514 shares of Common Stock voted for, 4,441,707 against, and 134,868 abstaining. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
Date: |
June 17, 2022 |
By: |
/s/ Michael Lowenstein |
|
|
|
Michael Lowenstein |